NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) — Kenneth Research has an in-depth market report on the ‘Global Anticholinergic Drugs Market‘ for the forecast period i.e. 2022-2031, which includes the following factors:
- Market growth over the forecast period
- Detailed regional summary
- market segmentation
- growth accelerator
- challenges
- Key market players and their detailed profiling
Global anticholinergic market size
The global Anticholinergic Drugs market generated approximately US$6.2 billion in 2021 and is set to grow at a CAGR of ~6% during the forecast period. The market expansion can be largely attributed to the world’s geriatric population, which is also a major contributor to the increased prevalence of numerous chronic diseases. The United Nations World Population Prospects 2019 report estimates that in 2019, 1 in 11 people will be over the age of 65 and that by 2050, 1 in 6 people are expected to be over the age of 65. The life sciences sector is projected also contribute significantly to market growth. In recent years, global healthcare spending has more than doubled, reaching nearly $8.5 trillion in 2019, or 9.8% of global GDP. The development and expansion of healthcare infrastructure and round-the-clock medical care are other variables that are likely to boost market progress.
Get a sample PDF of this report @ https://www.kennethresearch.com/sample-request-10116989
Global Anticholinergic Drugs Market: Key Insights
- The North American region accounts for the majority of sales
- Parkinson’s disease dominates the sales chart
- The hospital segment remains prominent in the segmentation of the sales channel
Increasing incidence of chronic diseases and growing online pharmacies are driving the market
More than 580 drugs have anticholinergic effects to some extent, several scientific data claim. Treatments for respiratory diseases (asthma, COPD), Parkinson’s disease, cardiovascular diseases, urge incontinence, physiological…
